Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer


Commonly used measures of comorbidity assess comorbidity number and type but not severity. We sought to evaluate the impact of comorbidity severity on longitudinal health-related quality of life (HRQOL) in men treated with radical prostatectomy (RP) or radiation therapy (RT) using the Total Illness Burden Index for prostate cancer (TIBI-CaP). We sampled 738 men with non-metastatic prostate cancer treated with RP or RT from the Cancer of the Prostate Strategic Urologic Research Endeavor registry. We examined the impact of comorbidity severity on generic and disease-specific HRQOL at baseline and at 6, 12, 18 and 24 months post-treatment. Men with worse TIBI-CaP comorbidity had significantly lower baseline and post-treatment HRQOL in all domains at all time points. In a multivariate model, men with moderate or severe TIBI-CaP comorbidity had significantly worse HRQOL scores at 12 and 24 months after treatment in all domains except sexual and urinary function (P<0.05); in these domains, severe comorbidity was predictive of lower HRQOL (P<0.05). Comorbidity groups had similar absolute declines in HRQOL from baseline to 6 and 24 months after treatment. Although comorbidity groups experienced similar long-term declines from baseline HRQOL after treatment, men with more severe comorbidity had significantly lower baseline scores and therefore poorer long-term HRQOL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4


  1. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J . Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631.

    Article  CAS  PubMed  Google Scholar 

  2. Fowler JE Jr TF, Renfroe DL . Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996; 156: 1714–1718.

    Article  PubMed  Google Scholar 

  3. Tewari A JC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M . Long-term survival probability in men with clinically localized prostate cancer: a case–control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171: 1513–1519.

    Article  PubMed  Google Scholar 

  4. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS et al. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology 2006; 67: 559–565.

    Article  PubMed  Google Scholar 

  5. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171: 703–707.

    Article  PubMed  Google Scholar 

  6. van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS . Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res 2008; 17: 845–855.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Albertsen PC FD, Storer BE, Kolon TF, Fine J . The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127–132.

    Article  PubMed  Google Scholar 

  8. Stier DM, Greenfield S, Lubeck DP, Dukes KA, Flanders SC, Henning JM et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 1999; 54: 424–429.

    Article  CAS  PubMed  Google Scholar 

  9. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH . Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 2007; 109: 1777–1783.

    Article  PubMed  Google Scholar 

  10. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 2004; 171: 1393–1401.

    Article  PubMed  Google Scholar 

  11. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1996; 48: 773–777.

    Article  CAS  PubMed  Google Scholar 

  12. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

    Article  CAS  Google Scholar 

  13. Greenfield S, Sullivan L, Dukes KA, Silliman R, D'Agostino R, Kaplan SH . Development and testing of a new measure of case mix for use in office practice. Med Care 1995; 33: AS47–AS55.

    CAS  PubMed  Google Scholar 

  14. Stewart AL, Hays RD, Ware Jr JE . The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724–735.

    Article  CAS  PubMed  Google Scholar 

  15. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH . The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002–1012.

    Article  CAS  PubMed  Google Scholar 

  16. Ware Jr JE, Kosinski M, Keller SK . SF- 36 Volume: Physical and Mental Health Summary Scales: A User′s Manual. The Health Institute New England Medical Center: Boston, MA, 1994.

    Google Scholar 

  17. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979–3986.

    Article  PubMed  Google Scholar 

  18. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–360.

    Article  CAS  PubMed  Google Scholar 

  19. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS . Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101: 888–892.

    Article  PubMed  Google Scholar 

Download references


The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is funded in part by an independent educational grant from Abbott Labs.

Author information

Authors and Affiliations


Corresponding author

Correspondence to T J Daskivich.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Daskivich, T., van de Poll-Franse, L., Kwan, L. et al. From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer. Prostate Cancer Prostatic Dis 13, 320–327 (2010).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • prostatic neoplasms
  • comorbidity
  • quality of life
  • outcome assessment
  • prostate

This article is cited by


Quick links